Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1954 1
1969 1
1984 1
1985 4
1986 4
1987 5
1988 5
1989 6
1990 4
1991 3
1992 7
1993 11
1994 15
1995 9
1996 12
1997 5
1998 7
1999 6
2000 10
2001 7
2002 13
2003 11
2004 10
2005 7
2006 8
2007 18
2008 19
2009 24
2010 13
2011 21
2012 14
2013 26
2014 13
2015 22
2016 13
2017 11
2018 12
2019 11
2020 11
2021 21
2022 9
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

408 results
Results by year
Filters applied: . Clear all
Page 1
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. Goldstraw P, et al. Among authors: eberhardt we. J Thorac Oncol. 2016 Jan;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009. J Thorac Oncol. 2016. PMID: 26762738 Free article.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Brahmer J, et al. Among authors: eberhardt we. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31. N Engl J Med. 2015. PMID: 26028407 Free PMC article. Clinical Trial.
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. Borghaei H, et al. Among authors: eberhardt wee. J Clin Oncol. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15. J Clin Oncol. 2021. PMID: 33449799 Free PMC article.
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Horn L, et al. Among authors: eberhardt wee. J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12. J Clin Oncol. 2017. PMID: 29023213 Free PMC article. Clinical Trial.
Too Good to be True?
Sebastian M, Stratmann JA, Eberhardt WEE. Sebastian M, et al. Among authors: eberhardt wee. J Thorac Oncol. 2021 Apr;16(4):507-508. doi: 10.1016/j.jtho.2021.01.1606. J Thorac Oncol. 2021. PMID: 33781437 Free article. No abstract available.
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M; CRISP Registry Group. Griesinger F, et al. Among authors: eberhardt w. Lung Cancer. 2021 Feb;152:174-184. doi: 10.1016/j.lungcan.2020.10.012. Epub 2020 Nov 2. Lung Cancer. 2021. PMID: 33358484 Free article.
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. Kelly K, et al. Among authors: eberhardt we. J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324372 Free article. Clinical Trial.
[The boundaries of curation].
Debus J, Eberhardt W, Hoffmann H, Passlick B, Rübe C, Thomas M. Debus J, et al. Among authors: eberhardt w. Onkologie. 2010;33 Suppl 5:12-20. doi: 10.1159/000313972. Epub 2010 May 14. Onkologie. 2010. PMID: 20523102 Free article. Review. German.
Cancer of unknown primary.
Freudenberg LS, Rosenbaum-Krumme SJ, Bockisch A, Eberhardt W, Frilling A. Freudenberg LS, et al. Among authors: eberhardt w. Recent Results Cancer Res. 2008;170:193-202. doi: 10.1007/978-3-540-31203-1_15. Recent Results Cancer Res. 2008. PMID: 18019627 Review.
408 results